IRVING, Texas --(BUSINESS WIRE)--Jun. 1, 2026-- Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and

Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance IRVING, Texas --(BUSINESS WIRE)--May 28, 2026-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the

Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp.

IRVING, Texas --(BUSINESS WIRE)--Apr. 22, 2026-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide first quarter

Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of

IRVING, Texas --(BUSINESS WIRE)--Feb. 25, 2026-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and

Perimenopause survey reveals widespread misdiagnoses undermining women’s health, with women turning to Google instead of doctors for information IRVING, Texas--( BUSINESS WIRE )--A groundbreaking national survey from  Biote , a leading innovator advancing the healthspan of patients’ lives by

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per

IRVING, Texas --(BUSINESS WIRE)--Oct. 22, 2025-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights